Seyed Abolfazl Mohsenizadeh, Mohsen Rajaeinejad, Mehran Khoshfetrat, Reza Arefizadeh, Seyed Hossein Mousavi, Reza Mosaed, Mohammad Hassan Kazemi-Galougahi, Hasan Jalaeikhoo, Ali Faridfar, Mohsen Nikandish, Sepideh Alavi-Moghadam, Babak Arjmand
Recent advancements in personalized treatments, such as anthracycline chemotherapy, coupled with timely diagnoses, have contributed to a decrease in cancer-specific mortality rates and an improvement in cancer prognosis. Anthracyclines, a potent class of antibiotics, are extensively used as anticancer medications to treat a broad spectrum of tumors. Despite these advancements, a considerable number of cancer survivors face increased risks of treatment complications, particularly the cardiotoxic effects of chemotherapeutic drugs like anthracyclines...
June 7, 2024: Advances in Experimental Medicine and Biology